Dingyao Hu

Peking University - Key Laboratory of Carcinogenesis and Translational Research

No. 38 Xueyuan Road

Haidian District

Beijing, Beijing 100871

China

  • Peking University - Key Laboratory of Carcinogenesis and Translational Research

SCHOLARLY PAPERS

1

DOWNLOADS

80

TOTAL CITATIONS

0

Scholarly Papers (1)

Actions:
Email selected abstracts
1.

Ibrutinib Combined With Low-Dose HDAC Inhibitor Chidamide Synergistically Enhances the Anti-Tumor Effect in B-Cell Lymphoma

Number of pages: 20 Posted: 31 Jan 2022
Hui Yu, Lan Mi, Weimin Zhang, Yingying Ye, Miaomiao Li, Dingyao Hu, Jiaowu Cao, Dedao Wang, Xiaogan Wang, Ning Ding, Yuqin Song and Zhu Jun
Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research and Peking University - Key Laboratory of Carcinogenesis and Translational Research
Downloads 80 (672,779)

Abstract:

Loading...

BTK inhibitor, HDAC inhibitor, B-cell lymphoma, Drug combination, Tumor microenvironment